A Cochlear sound processor made for Apple mobile devices gets greenlight from FDA

Apple | July 27, 2017

Apple is continuing to bolster its profile in the medtech space, this time through Australian cochlear implant maker Cochlear Limited. The medical device business is launching the first implant sound processor made for iPhones, iPads and iPods in September after receiving clearance from the U.S. Food and Drug Administration in June. Sound processors send signals to the electrodes in a cochlear implant that has been surgically placed in the inner ear, or cochlea, for people who are hard-of-hearing. The Cochlear Nucleus Implant users can stream sound from a compatible iPhone, iPad and iPod touch directly to their sound processor, Cochlear Ltd said in a press release.

Spotlight

Fast growing healthcare biotech company, Amplyx Pharmaceuticals, chooses LBMC Technology Solutions to implement Sage Intacct's cloud-accounting solution.


Other News
HEALTHTECH SECURITY, DIGITAL HEALTHCARE

CereCore® expands healthcare technology services into the UK

CereCore® | December 09, 2022

CereCore announced they are expanding their healthcare information technology (IT) services including electronic patient record (EPR), technical and IT staffing services into the United Kingdom in order to support the digital transformation that will help patients, clinicians and carers to manage and view healthcare records. "For close to 30 years, we have been serving communities in the US by supporting hospitals and clinics through the various stages of healthcare technology adoption from EPR implementations and infrastructure to support. There's momentum in the UK for a single patient record, more clinical decision support and efficient healthcare. CereCore has the skills and expertise needed to help care providers accomplish the tremendous amount of work that lies ahead to meet the NHS regulatory requirements and public health goals," said Curtis Watkins, president and CEO, CereCore. The international team will employ a range of roles specializing in EPR applications, cloud, network and infrastructure, IT staffing and recruiting, business operations, management and administrative roles. CereCore will also rely upon clinical, EPR and technical experts on their US-based team to assist with digitalisation projects, which will help them quickly ramp up to meet project staffing needs and recruit for specialized technology skillsets. "We have a US team with decades of experience as nurses, clinicians and healthcare technologists, and they have been consulting on IT projects remotely for years," said Craig McCollum, vice president of MEDITECH international services. "Our vision for expanding internationally is to do our part to improve healthcare delivery by offering what we do best — healthcare technology services. We understand what it takes to appropriately staff technology implementation projects and find the best talent for the job, whether that team member is located locally in the UK, US or elsewhere." CereCore has been working closely with HCA Healthcare UK and HealthTrust Europe as well as several other leading technology companies. "We expect our partnerships to deepen and to work collaboratively with partners and care systems to provide the services and support needed to create an integrated EPR in the UK," said Watkins. About CereCore CereCore® provides IT services that make it easier for you to focus on supporting hospital operations and transforming healthcare through technology. With a heritage rooted in top-performing U.S. hospitals, we serve as leaders and experts in technology, operations, data security, and clinical applications. We partner with clients to become an extension of the team through comprehensive IT and application support, technical professional and managed services, IT advisory services, and EHR consulting, because we know firsthand the power that integrated technology has on patient care and communities.

Read More

DIGITAL HEALTHCARE, MEDICAL DEVICES

mPulse Expands Streaming Engagement Capabilities for Consumer-Focused Digital Health Content

mPulse Mobile, | December 16, 2022

mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, announced the launch of new content capabilities and streaming courses that address health literacy barriers in a consumer-friendly format. Several solution advances continue mPulse’s focus on integrating streaming content into digital health engagement strategies, creating an industry-leading combination of conversational AI that drives two-way SMS messaging campaigns and powerful health streaming content to engage, delight, and move consumers to adopt healthy behaviors. “Stories” Video Format mPulse launched the stories video format to deliver more impactful content experiences in consumer-focused outreach programs. The format adapts video “stories” commonly seen in social media platforms like TikTok and Instagram Reels to deliver captivating content on important healthcare topics. mPulse’s Health Activation Platform tailors the stories content to the individual to address important engagement challenges such as medication adherence, gaps in care, and health plan navigation. “These new video capabilities are proof that mPulse Mobile continues to pioneer category-defining member engagement technology. Our highly tailored, consumer focused content is a powerful tool that creates culturally sensitive digital experiences to address health disparities, encourage healthy behaviors, and drive member outcomes. The stories format allows us to be more impactful when consumers engage, and our initial results show they have a significant impact on program goals.” Bob Farrell, CEO of mPulse Mobile The format drives increased engagement and improved health outcomes among targeted populations. mPulse deployed the stories format in a diabetes eye-screening outreach program. The program included 200,000 Medicare Advantage members, with a subset of 100,000 members receiving the streaming content, delivered in a stories format. This cohort showed a 274% higher Call to Action completion rate than members who did not receive the stories-formatted content. Leveraging conversational outreach, consumers are prompted on the issues that might be preventing them from completing a given action. When they respond via text to identify a barrier, tailored streaming content is delivered instantly and in real-time via an embedded link to address the barrier. New Health Educational Courses mPulse has also launched new streaming health courses that address key health issues and improve health literacy in a consumer-friendly digital format. Produced with proven learning techniques and behavioral science, these courses allow healthcare organizations to extend the digital experience from initial outreach to deep, relationship-building experiences. “Our product strategy aims to offer the most effective technology at delivering health engagement, and core to mPulse’s value is meaningful digital content, which elevates engagement experiences to a new level,” said Sanjeev Sawai, Chief Product and Technology Officer at mPulse Mobile. “Members are in need of better educational content that they find engaging and worth their time. We use short, captivating content to get members' attention and motivate them to act in healthy ways - ways that help them build their health literacy, prevent diseases, manage conditions, and foster wellbeing. Our approach offers innovative frictionless ways to encourage members to engage deeply in their own health and healthcare.” About mPulse Mobile mPulse Mobile is reimagining health engagement to inspire healthier lives and deeper relationships between healthcare organizations and their consumers. A leading healthcare Conversational AI platform combines with award-winning health education for the streaming age to deliver tailored digital health engagement that nurtures, educates, and activates healthcare consumers. With more than a decade of experience, 150+ healthcare customers and 1 billion conversations annually, mPulse Mobile has the data, the expertise, and the solutions to drive healthy behavior change.

Read More

MEDICAL DEVICES

Study Reveals Florence Healthcare’s Site Enablement Platforms Can Accelerate Clinical Trials by Six Weeks and Reduce Costs by Over $1M per Study

Florence Healthcare | November 18, 2022

Florence Healthcare™, a clinical research technology company headquartered in Atlanta, Georgia, announced the completion of a year-long third-party study on the impact of Site Enablement Platforms™ on clinical research timelines and costs. The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor portals and new Site Enablement Platforms on research sponsor and Contract Research Organization study timelines and budgets. “Pharma sponsors and CROs realize the importance of enabling sites to do their best work - but only recently have they discovered that traditional site portals are more hindrance than help. Yet, these organizations weren't able to measure the true impact of switching to a Site Enablement Platform. This year-long study aimed to fix that and highlight how linking fragmented workflows accelerates the full lifecycle of clinical trials.” Ryan Jones, CEO of Florence Healthcare Site enablement is a new technology category that prioritizes the needs of the site, a major shift from past technology that only looked at the experience of the sponsor. These platforms, including Florence Healthcare’s SiteLink™, insist on ease-of-use and ease-of-setup for the site, quality support, and simplified integrations. SiteLink works in conjunction with eBinders™, an electronic Investigator Site File solution used by over 12,000 research sites in 45 countries. About the Study Marketcap Consulting conducted interviews with clinical research operations leaders harnessing SiteLink, examined timelines and study costs, and analyzed the impact across the sites in the study. On average, the team found that SiteLink accelerated study start-up by four weeks and study close-out by two weeks at every site. For a 50-site study, this six-week acceleration reduced cash burn by one million dollars. “We can see a clear positive impact on study timelines and cash burn when research sponsors and CROs implement Site Enablement Platforms,” said Joel White, founder of Marketcap Consulting. “This early study reveals that by enabling sites to do their best work, the clinical research industry unlocks value across the full research cycle.” “While the financial impact of switching to SiteLink makes investing in site enablement an easy choice for sponsors and CROs, it’s really the acceleration of studies that gets our team at Florence Healthcare excited,” said Jones. “We aim to double the output of research teams by the end of the decade, and enabling sites is the way to do it.” About Florence Healthcare Florence Healthcare’s clinical trial software helps more than 12,000 research sites in 45 countries manage their documents, data, and workflows. The Florence Healthcare™ platform also provides remote access so sponsors and Contract Research Organizations can collaborate with their sites around the world. Florence Healthcare users now perform 5.8 million remote monitoring activities each month.

Read More

FUTURE OF HEALTHCARE

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

Abbott | November 21, 2022

Abbott has been recognized by the Consumer Technology Association with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show the most influential technology event in the world. Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards, all within the Digital Health award category Aveir VR Leadless Pacemaker – The world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable. The system was developed by Abbott to treat patients with slow heart rhythms and eliminates wires used to deliver therapy in traditional pacemakers. Proclaim Plus SCS System – Abbott's latest advancement in neurostimulation therapy to treat chronic pain using low doses of targeted BurstDR™ stimulation that can be adjusted as a person's therapeutic needs evolve across up to six areas of the body, which is more pain sites in the body than ever before. Alinity m Monkeypox PCR test1 – A first of its kind, Abbott received FDA Emergency Use Authorization of its PCR test for detecting the monkeypox virus. The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products. The program recognizes the year's most innovative products in a multitude of consumer technology product categories and distinguishes the highest-rated in each. Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years. Other Abbott products previously honored with CES Innovation Awards include FreeStyle Libre 32, the world's smallest, thinnest3 and most accurate4 14-day glucose sensor and a CES 2022 Best of Innovation Award winner; BinaxNOW™5, the #1 COVID-19 self test in the U.S.; and the UltreonTM 1.0 intravascular imaging and coronary physiology software platform, which helps guide and optimize stenting decisions, combining optical coherence tomography with artificial intelligence. In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation. The FreeStyle Libre portfolio has transformed the lives of approximately 4.5 million people6 living with diabetes globally. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.

Read More